Substituted pyrrolidines as SYK inhibitors
The present disclosure relates to compounds that are Syk inhibitors and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, the structure of the compounds is given by Formula I:wherein X1, X2, X3, R2, R3, R4, R5, and Y are as described herein. The present disclosure further provides pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by Syk.
Gilead Sciences, Inc.
C A C A C C C A A C A A C A A C C C C A C A A A A C A C A A
C07D A61P C07D A61P C07D C07D C07D A61P A61P C07D A61P A61P C07D A61P A61P C07D C07D C07D C07D A61P C07D A61P A61P A61P A61P C07D A61P C07D A61P A61P
inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional
Juan A. Gregory Michael Jiayao Ashley A. Nicholas Zhimin Adam J. John O. Darryl JinMing Jeffrey Aaron C. Jayaraman Jeff Sheila Scott E. Kevin S. Peter Zheng-Yu Jianjun Chandrasekar Zhongdong Hyung-jung Kirk L. Scott A. Seung H. Julie William J. Jennifer R.
Guerrero Notte Sangi Li Katana Mai Du Schrier Link Kato Xiong Kropf Schmitt Chandrasekhar Zablocki Zipfel Lazerwith Currie Blomgren Yang Xu Venkataramani Zhao Pyun Stevens Mitchell Lee Farand Watkins Lo